Table 1.
Patient Demographics (n = 53)
| Age, y | |
| Median | 62 |
| Range | 38–86 |
| Sex | |
| Men | 34 (64%) |
| Women | 19 (36%) |
| ECOG performance status | |
| 0 | 16 (30%) |
| 1 | 29 (55%) |
| 2 | 8 (15%) |
| Stage | |
| IIIC | 1 (2%) |
| IV | 52 (98%) |
| Primary site | |
| Cutaneous | 42 (79%) |
| Ocular | 5 (9%) |
| Mucosal | 3 (6%) |
| Unknown | 3 (6%) |
| LDH | |
| ≤ULN (200 U/L) | 23 (43%) |
| 1.1 to ≤2× ULN | 13 (25%) |
| >2× ULN | 17 (32%) |
| Prior therapy | |
| Radiotherapy | 21 (40%) |
| Cytotoxic chemotherapy | 49 (93%) |
| Biologic therapy | |
| Adjuvant IFN-α (adjuvant) | 9 (17%) |
| High-dose IL-2 (metastatic disease) | 8 (15%) |
| Vaccine therapy | 4 (7%) |
| Others (eg, small molecule inhibitors) | 23 (43%) |
| No. of prior systemic therapies | |
| Median | 2 |
| Range | 0–6 |
ECOG indicates Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal; IFN-α, interferon-α; IL-2, interleukin-2.